Eli Lilly and
Quarterly Financials
| Values in thousands | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
Revenue | $17,600,800 | $15,557,700 | $12,728,500 | $13,532,800 |
Gross Profit | 14,592,500 | 13,109,900 | 10,504,300 | 11,129,000 |
EBITDA | 7,882,000 | 7,503,900 | 4,162,600 | 5,748,200 |
EBIT | 7,412,000 | 7,025,400 | 3,699,800 | 5,263,400 |
Net Income | 5,582,500 | 5,660,500 | 2,759,300 | 4,409,800 |
Net Change In Cash | 17,600,800 | 15,557,700 | 12,728,500 | 13,532,800 |
Free Cash Flow | 8,612,000 | 1,283,000 | -1,600,900 | 726,600 |
Cash | 9,791,900 | 3,375,900 | 3,093,300 | 3,268,400 |
Basic Shares | 898,800 | 899,793 | 900,604 | 903,158 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $45,042,700 | $34,124,100 | $28,541,400 | $28,318,400 |
Gross Profit | 36,624,400 | 27,041,900 | 21,911,600 | 21,005,600 |
EBITDA | 15,227,600 | 8,567,800 | 8,660,500 | 8,042,900 |
EBIT | 13,461,000 | 7,040,500 | 7,138,000 | 6,495,300 |
Net Income | 10,590,000 | 5,240,400 | 6,244,800 | 5,581,700 |
Net Change In Cash | 45,042,700 | 34,124,100 | 28,541,400 | 28,318,400 |
Cost of Revenue | -1,583,900 | |||
Free Cash Flow | 414,300 | -3,152,000 | 4,600,400 | 5,387,500 |
Cash | 3,268,400 | 2,818,600 | 2,067,000 | 3,818,500 |
Basic Shares | 904,059 | 903,284 | 950,182 | 953,653 |
Earnings Calls
| Quarter | EPS |
|---|---|
2025-12-31 | $0 |
2025-09-30 | $7.02 |
2025-06-30 | $6.31 |
2025-03-31 | $3.34 |
